Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms
Indian Firm May See Fortunes Change As ZyCov-D And Biosimilars Reach Market
Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.
You may also be interested in...
Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.
Zydus Cadila’s single-dose nelarabine injection (250mg/50ml) will enjoy 180 days of competitive generic therapy market exclusivity following approval from the US FDA, as the first approved rival to Novartis’ Arranon brand.
The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.